

CUPID LIMITED

Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits

Date: - 05/08/2024

To,

Department of Corporate Services,

BSE LIMITED,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001

SCRIP CODE: 530843

The National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor, Bandra-Kurla

Complex, Bandra (East),

Mumbai - 400051

Fax No. - 6641 8125 / 26

SCRIP CODE: CUPID

Subject: - Outcome of Board Meeting and Financial Results for Quarter ended 30th June, 2024

Dear Sir / Madam,

With reference to captioned subject, we attached herewith the detail statement of outcome of Board Meeting and Financial Results for quarter ended 30th June, 2024 pursuant to regulation 30 and regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 respectively.

Kindly take the same on your records and acknowledge the receipt.

By the order of the Board of Directors


For Cupid Limited

Saurabh V. Karmase

Company Secretary and Compliance Officer









CUPID LIMITED

Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits

OUTCOME OF BOARD MEETING

August 5th, 2024:

The Board of Directors of Cupid Limited at its meeting held on August 5th, 2024, inter alia, had considered and approved the following matters: -

Commencement time of Board Meeting: - 05 .45 P.M.

Conclusion time of Board Meeting: - 06 . 40 P.M.

- Quarterly reports submitted to BSE Limited and National Stock Exchange of India Limited for quarter ended 30th June, 2024 were considered and reviewed by the Board.
- 2. Unaudited Financial results for quarter ended 30th June, 2024 were considered and adopted by the Board. (Financial Results attached as Annexure-I)
- 3. The Directors Report for year ended 31st March, 2024 was considered and approved by the Board.
- The Notice to Members / Shareholders for 31st Annual General Meeting of the company was considered and approved by the Board.
- 5. Formation / Incorporation of a Wholly Owned Subsidiary of the company in United Arab Emirates (UAE).

The incorporation of the abovementioned wholly owned subsidiary in United Arab Emirates (UAE) will expand the business opportunities of the Company.



Factory & Registered Office:









Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits

Enclosed herewith are the details required under Regulation 30 of Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015. (Annexure-II)

Place: - Mumbai

Date: - 05/08/2024


By the order of the Board of Directors

For Cupid Limited

Saurabh V. Karmase

Company Secretary and Compliance Officer

Factory & Registered Office:







Partners:
Sohan Chaturvedi
Chaturvedi V N
Noshir B Captain
Rajiv Chauhan
Neha Chauhan
Shristi Chaturvedi
Prakash Mistry
FCA



FRN - 118424W

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Limited Review Report to The Board of Directors CUPID LIMIED

- 1. We have reviewed the accompanying statement of unaudited financial results of Cupid Ltd (the "Company") for the quarter ended June 30, 2024 being submitted by the Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is express conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with standards on Auditing specifies under section 143(10) of the Act. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid' Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting

Page 1 of 2



principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi Sohan & Co.

Chartered Accountants

FRN: 118424W

Vivekanand Chaturvedi

Partner

Membership No.: 106403 UDIN: **24106403BKBFIV3505** Place: Mumbai

Date: 05th August, 2024

Cupid Limited

CIN No: L25193MH1993PLC070846

Regd. Office: - A-68, M.I.D.C. (Malegaon), Sinnar, Nashik – 422113, Maharashtra, India.

Ph:- 02551-230280, Fax:- 02551-230279, Website: www.cupidlimited.com, Email- info@cupidlimited.com

Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2024

		Quarter Ended On			Year Ended on
S.No.	100 March 100 Ma		un-2024 31-Mar-2024		31-Mar-2024
	115.00	(UnAudited)	(Audited)	(UnAudited)	(Audited)
1	Revenue from operation	3,913.32	6,289.74	3,367.60	17,108.87
2	Other Non - operation Incomes	489.28	298.04	152.17	721.62
	Total Income	4,402.60	6,587.78	3,519.77	17,830.49
3	Expenses				
a)	Cost of Material Consumed	1,229.48	1,533.66	1,187.28	5,553.99
b)	Purchase of Stock-In-Trade	241.66	30.66		30.66
c)	Change in Inventories	(99.61)	763.82	(6.07)	344.14
d)	Employee benefit expenses	628.91	449.41	487.57	1,641.16
e)	Finance costs	23.19	94.11	40.32	181.02
n	Depreciation	75.63	73,69	71.40	292.54
g)	Other Expenses	1,246.97	421.81	1,516.70	4,528.80
	Total Expenses	3,346.23	3,367.16	3,297.20	12,572.31
4	Profit from Continuing Operation Before Exceptional items and Taxes	1,056.37	3,220.62	222.57	5,258.18
5	Profit From Ordinary Activities Before Tax	1,056.37	3,220.62	222.57	5,258.18
6	Less : Tax Expenses			18/06/ 020/05	2 2 7 7 7 0 7 7 8 7 7 8 8 8
a)	Income tax for current quarter/ year	261.82	813.85	88.18	1,260.77
b)	Short / (Excess) provision of earlier years	-	(2.40)	±=	(2.40)
c)	Deferred Tax Expenses / (Credit)	(30.96)	37.46	(81.40)	14.33
7	Net Profit / (Loss) From Ordinary Activities after tax for the period	825.51	2,371.71	215.79	3,985.48
8	Other Comprehensive Income / (Loss) (Net of Tax)				
a)	Item that will not be reclassified to profit and loss account				
(i)	Remeasurement of employee defined benefit obligation	*	(19.68)		(64.07)
(ii)	Income Tax relating to items that will not be reclassified to profit or loss		4.95	필	16.12
ŋ	Total Comprehensive Income (after tax) for the period	825,51	2,356.98	215.79	3,937.53
10	Paid up Equity Share Capital (Face value Rs. 1 /-)	2,684.67	2,683.55	2,667.60	2,683.55
11	Earning Per Share (EPS) *(Not sunualised)				
a)	Basic EPS (Amount is ₹)	0.31*	0.88*	0.08*	1.49
b)		0.30*	0.87*	0.07*	1,47

699.72	1,670.88	699.72	2,538.46	Total Liabilities
86.44	189.47	86.44	1,837.35	c) Others / Unallocated
	22.08		31.40	b) Vitro Diagnostic Device (IVD)
613.28	1,459.33	613.28	669.71	a) Male and Female Contraceptives & Jelly
				4 Segment Liabilities
30,828.18	19,118.28	30,828.18	33,515.66	Total Assets
18,217.16	11,774.24	18,217.16	21,172.41	c) Others / Unallocated
957.43	822.31	957.43	1,058.12	b) In Vitro Devices (IVD)
11,653.59	6,521.73	11,653.59	11,285.13	3 Segment Assets a) Male and Female Contraceptives & Jelly
3,430.10	444.31	3,220.02	1,000.37	TOTAL FLOTE DESOFE TAX
2 350 10	777 57	בא חוו ג	1 056 17	Total Brofit Bafons Tax
729.29	152.17	305.71	443.46	c) Others / Unallocated
(89.14)	(33.52)	(12.00)	20.65	b) In Vitro Devices (IVD)
4,618.03	103.92	2,926,91	592.26	a) Maie and Female Contraceptives & Jelly
				2 Segment Results Profit/(Loss) Before Tax
. ojovos	ojessoci	ojeonio	1, 100,000	CLOSID AND CHILD IN CHILDREN OF PROPERTY OF THE COLOR
17 830 49	3 510 77	6 587 78	4 400 60	Cross Devenue from sale of product & Service
1			1	Less: Inter Segment Revenue
17,830.49	3,519.77	6,587.78	4,402.60	Total
1,075.54	152.17	651.76	489.28	-Other Income
30.66	,	30.66	242.48	-Sale of Trading Goods
r r				c) Others / Unallocated
331.57	14.98	125.58	158.94	b) In Vitro Devices (IVD)
16,392.92	3,352.62	5,779.78	3,511.90	 a) Male and Female Contraceptives & Jelly
				1 Segment Revenue
(Audited)	(UnAudited)	(Audited)	(UnAudited)	
31-Mar-2024	30-Jun-2023	31-Mar-2024	30-Jun-2024	Particular
Year Ended on		Quarter Ended on)	
(₹ in Lacs)			Zim zi	0
		ad 30Th Tune 2024	Seement Information For The Operator Ended 20Th June 2024	Seement Informati
			CIEDII I CIEDI	The state of the s



Notes to the Quarterly Result: -

1. The above financial results have been reviewed and recommended for approval by the Audit

Committee to the Board of Directors and have been approved by the Board of Director at its

meeting held on 5th August, 2024.

2. Financial results for all the periods presented have been prepared in accordance with the

recognition and measurement principle of Ind AS notified under the Companies (Indian

Accounting Standard) Rules, 2015 as amended from time to time.

3. The company's business operation comprises of operating segments viz., Male and Female

contraceptives, other relevant products and In Vitro Devices (IVD).

4. The Board of Directors authorised Mr. Aditya Halwasiya, Managing Director, to sign the

standalone financial results of the company for quarter ended 30th June, 2024.

5. The figures for quarter ended 31st March, 2024 are arrived at difference between audited

figures in respect of full financial year and published figure upto nine months of relevant

financial year.

6. The previous period / year financial figures have been regrouped / rearranged wherever

necessary to make them comparable.

7. The results of the Company are available for investors at https://www.cupidlimited.com/,

https://www.nseindia.com/ and https://www.bseindia.com/

Place: Mumbai

For and on behalf of

Date: 5th August, 2024

Cupid Limited

Mr. Aditya Halwasiya

(Managing Director)



Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits

Annexure-II

1.	Name	of the	target	entity,	details	in
br	ief such	n as si	ze, turn	over et	c.	

Names of the proposed Company:

CUPID UAE LIMITED or CUPID CUPID INVESCO LIMITED or INVESTMENTS LIMITED or any other name approved by the authorities in Jebel Ali Free Zone, Jebel Ali, Dubai, United Arab Emirates.

Proposed Authorised Capital:

200 Fully Paid up Equity Shares of AED 1,000 each aggregating to AED 2,00,000.

2. Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".

The Wholly Owned Subsidiary (WOS) company once incorporated will be a related party of the company.

- Save and except what is mentioned above, the promoter / promoter group / group companies are not interested in the transaction.
- 3. Industry to which the entity being acquired belongs.
- Pharmaceuticals and FMCG
- 4. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).

The incorporation of WOS in UAE would give vast business exposure to the Company in Gulf Countries.

CIN No.: L25193MH1993PLC070846







Factory & Registered Office:



CUPID LIMITED

Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits

5. Brief details of any governmental or	Not Applicable
regulatory approvals required for the	
acquisition.	
	Not Applicable
6. Indicative time period for completion	Not Applicable
of the acquisition.	
7. Nature of consideration - whether	100% subscription to the share capital
cash consideration or share swap and	in cash.
details of the same.	
8. Cost of acquisition or the price at	Not Applicable
which the shares are acquired.	
9. Percentage of shareholding / control	100%
acquired and / or number of shares	
acquired.	
10. Brief background about the entity	Not Applicable since the Company is
acquired in terms of products / line of	yet to be incorporated.
business acquired, date of	
incorporation, history of last 3 years	
turnover, country in which the acquired	
entity has presence and any other	
significant information (in brief).	

Necessary updates shall be provided once the proposed company is incorporated.



Factory & Registered Office:





